Companies Vigilant As China Expands Wide-Ranging Anti-Espionage Legislation
Exit Bans Also Widened
The recent arrest of a local Japanese employee of Astellas triggered alarms for pharma firms operating in China, while a newly-expanded and wide-ranging anti-espionage law means that sponsors must pay careful attention to overseas data transfers, especially related to clinical trials, business intelligence and due diligence, as well as other activities.
You may also be interested in...
AstraZeneca is reportedly considering joining a prominent investment fund to spin off and list its Chinese entities, in an apparent bid to better insulate them against potential geopolitical risks.
China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.
Cipla to pursue two-site, de-risked filing approach for large respiratory assets even as it awaits an FDA compliance classification for its Indore facility, which will determine the launch timelines for its much-awaited generic Advair in the US.